Key result
Low-dose heparin and early sheath removal may reduce bleeding risk with GPIIb/IIIa inhibitors.
Why the study?
Bleeding complications following platelet GPIIb/IIIa receptor antagonist use limit its effectiveness in PCI and acute ischemic syndromes.
How can bleeding complications be reduced in patients receiving platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary interventions or acute ischemic syndromes?
How can bleeding complications be reduced in patients receiving platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary interventions or acute ischemic syndromes?
Bleeding complications associated with GPIIb/IIIa inhibitors during PCI can be mitigated by using low-dose weight-adjusted heparin, avoiding postprocedural heparin, and early sheath removal.
May support bleeding mitigation strategies with GPIIb/IIIa inhibitors; leaves open randomized confirmation before practice change.
Platelet glycoprotein (GP) IIb/IIIa receptor antagonists are being used with increasing frequency in the settings of percutaneous coronary interventions and acute ischemic syndromes. The development of bleeding complications following GPIIb/IIIa blockade represents a significant limitation to its effectiveness. Baseline characteristics predictive of future bleeding events in patients receiving platelet GPIIb/IIIa receptor antagonist include older age, low body weight, evolving myocardial infarction, and female sex. In patients undergoing percutaneous coronary interventions with adjunctive GPIIb/IIIa inhibition, the risk of bleeding, particularly from the femoral vascular access site, may be reduced through the use of low-dose, weight-adjusted heparin (70 U/kg), avoidance of postprocedural heparin, and early vascular sheath removal. Strategies to reduce the incidence of bleeding complications in patients receiving GPIIb/IIIa inhibitors are proposed in this article.
No takes yet. Share an insight, caveat, or question.
Madan et al. (1999) conducted a review in Patients receiving platelet GPIIb/IIIa receptor antagonists. Platelet glycoprotein IIb/IIIa receptor antagonists was evaluated on Bleeding complications. In patients receiving GPIIb/IIIa inhibitors, bleeding risk may be reduced by using low-dose, weight-adjusted heparin (70 U/kg), avoiding postprocedural heparin, and early vascular sheath removal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: